Sentiment-Signal
15,7
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 13.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | f the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
Stammdaten
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Unternehmen & Branche
| Name | Solid Biosciences Inc. |
|---|---|
| Ticker | SLDB |
| CIK | 0001707502 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 581,8 Mio. USD |
| Beta | 2,58 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2022-12-31 | 10-K | 8,094,000 | -10.10 | 260,252,000 | 211,666,000 | |
| 2021-12-31 | 10-K | 13,620,000 | -10.14 | 232,380,000 | 208,211,000 | |
| 2021-09-30 | 10-Q | -17,983,000 | -2.40 | 248,986,000 | 223,363,000 | |
| 2021-06-30 | 10-Q | -18,695,000 | -0.17 | 265,857,000 | 237,938,000 | |
| 2021-03-31 | 10-Q | -16,900,000 | 285,279,000 | 253,000,000 | ||
| 2020-12-31 | 10-K | 0 | -25.50 | 171,169,000 | 132,086,000 | |
| 2020-09-30 | 10-Q | 0 | -21,246,000 | 40,518,000 | 22,231,000 | |
| 2020-06-30 | 10-Q | 0 | -18,987,000 | 57,963,000 | 40,713,000 | |
| 2020-03-31 | 10-Q | 0 | -26,694,000 | 73,960,000 | 56,456,000 | |
| 2019-12-31 | 10-K | -117,223,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-18 | Ganot Ilan | Director | Open Market Sale | -2,658 | 5.82 | -15,478.33 | -16,7% | |
| 2026-02-18 | Hanrahan Jessie | Officer, Chief Regulatory Officer | Open Market Sale | -4,134 | 5.82 | -24,073.52 | -26,0% | |
| 2026-02-18 | Cumbo Alexander | Director, Officer, President and CEO | Open Market Sale | -16,644 | 5.82 | -96,923.01 | -104,8% | |
| 2026-02-18 | Tan Kevin | Officer, CFO & Treasurer | Open Market Sale | -5,404 | 5.82 | -31,469.11 | -34,0% | |
| 2026-02-18 | Brooks Gabriel | Officer, Chief Medical Officer | Open Market Sale | 0 | 5.82 | 0.00 | 0,0% | |
| 2026-02-18 | Howton David T | Officer, Chief Operating Officer | Open Market Sale | -7,469 | 5.82 | -43,494.23 | -47,0% | |
| 2026-02-18 | Herzich Paul | Officer, Chief Technology Officer | Open Market Sale | -3,616 | 5.82 | -21,057.05 | -22,8% | |
| 2026-02-04 | Tan Kevin | Officer, CFO & Treasurer | Open Market Sale | -14,783 | 6.44 | -95,230.61 | -103,0% | |
| 2026-02-04 | Cumbo Alexander | Director, Officer, President and CEO | Open Market Sale | -48,913 | 6.44 | -315,092.65 | -340,8% | |
| 2026-02-04 | Hanrahan Jessie | Officer, Chief Regulatory Officer | Open Market Sale | -12,348 | 6.44 | -79,544.58 | -86,0% | |
| 2026-02-04 | Herzich Paul | Officer, Chief Technology Officer | Open Market Sale | -10,905 | 6.44 | -70,248.92 | -76,0% | |
| 2026-02-04 | Howton David T | Officer, Chief Operating Officer | Open Market Sale | -18,894 | 6.44 | -121,713.26 | -131,6% | |
| 2026-02-04 | Brooks Gabriel | Officer, Chief Medical Officer | Open Market Sale | -12,616 | 6.44 | -81,271.01 | -87,9% | |
| 2026-02-04 | Ganot Ilan | Director | Open Market Sale | -7,205 | 6.44 | -46,413.89 | -50,2% | |
| 2026-02-02 | Brooks Gabriel | Officer, Chief Medical Officer | Open Market Sale | -28,335 | 6.44 | -182,389.56 | -197,2% | |
| 2026-02-02 | Cumbo Alexander | Director, Officer, President and CEO | Open Market Sale | -80,258 | 6.44 | -516,612.72 | -558,7% | |
| 2026-02-02 | Tan Kevin | Officer, CFO & Treasurer | Open Market Sale | -26,837 | 6.44 | -172,747.09 | -186,8% | |
| 2026-02-02 | Hanrahan Jessie | Officer, Chief Regulatory Officer | Open Market Sale | -26,535 | 6.44 | -170,803.14 | -184,7% | |
| 2026-02-02 | Herzich Paul | Officer, Chief Technology Officer | Open Market Sale | -26,250 | 6.44 | -168,968.63 | -182,7% | |
| 2026-02-02 | Howton David T | Officer, Chief Operating Officer | Open Market Sale | -37,771 | 6.44 | -243,128.15 | -262,9% | |
| 2026-01-28 | Ganot Ilan | Director | Open Market Sale | -191 | 6.59 | -1,258.69 | -1,4% | |
| 2026-01-13 | Tan Kevin | Officer, CFO & Treasurer | Open Market Sale | -5,704 | 5.27 | -30,060.08 | -32,5% | |
| 2026-01-05 | Ganot Ilan | Director | Open Market Sale | -1,053 | 5.43 | -5,717.79 | -6,2% | |
| 2025-12-03 | Cumbo Alexander | Director, Officer, President and CEO | Open Market Sale | -10,808 | 5.11 | -55,228.88 | -59,7% | |
| 2025-12-03 | Howton David T | Officer, Chief Operating Officer | Open Market Sale | -4,932 | 5.11 | -25,202.52 | -27,3% | |
| 2025-12-03 | Herzich Paul | Officer, Chief Technology Officer | Open Market Sale | -2,701 | 5.11 | -13,802.11 | -14,9% | |
| 2025-12-03 | Hanrahan Jessie | Officer, Chief Regulatory Officer | Open Market Sale | -4,483 | 5.11 | -22,908.13 | -24,8% | |
| 2025-11-10 | Ganot Ilan | Director | Open Market Sale | -3,278 | 4.12 | -13,505.36 | -14,6% | |
| 2025-10-20 | Brooks Gabriel | Officer, Chief Medical Officer | Open Market Sale | -2,895 | 5.96 | -17,254.20 | -18,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.